key: cord-0973912-oj5psfyf
authors: Kiyasu, Yoshihiko; Owaku, Masato; Akashi, Yusaku; Takeuchi, Yuto; Narahara, Kenji; Mori, Sunao; Nagano, Takashi; Notake, Shigeyuki; Ueda, Atsuo; Nakamura, Koji; Ishikawa, Hiroichi; Suzuki, Hiromichi
title: Clinical evaluation of the rapid nucleic acid amplification point-of-care test (Smart Gene SARS-CoV-2) in the analysis of nasopharyngeal and anterior nasal samples()
date: 2021-12-31
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2021.12.027
sha: 69f9a00226bf7f29783845ef4cd2ac2327b05941
doc_id: 973912
cord_uid: oj5psfyf

INTRODUCTION: Smart Gene is a point-of-care (POC)-type automated molecular testing platform that can be performed with 1 min of hands-on-time. Smart Gene SARS-CoV-2 is a newly developed Smart Gene molecular assay for the detection of SARS-CoV-2. The analytical and clinical performance of Smart Gene SARS-CoV-2 has not been evaluated. METHODS: Nasopharyngeal and anterior nasal samples were prospectively collected from subjects referred to the local PCR center from March 25 to July 5, 2021. Two swabs were simultaneously obtained for the Smart Gene SARS-CoV-2 assay and the reference real-time RT-PCR assay, and the results of Smart Gene SARS-CoV-2 were compared to the reference real-time RT-PCR assay. RESULTS: Among a total of 1150 samples, 68 of 791 nasopharyngeal samples and 51 of 359 anterior nasal samples were positive for SARS-CoV-2 in the reference real-time RT-PCR assay. In the testing of nasopharyngeal samples, Smart Gene SARS-CoV-2 showed the total, positive and negative concordance of 99.2% (95% confidence interval [CI]: 98.4–99.7%), 94.1% (95% CI: 85.6–98.4%) and 99.7% (95% CI: 99.0–100%), respectively. For anterior nasal samples, Smart Gene SARS-CoV-2 showed the total, positive and negative concordance of 98.9% (95% CI: 97.2–99.7%), 98.0% (95% CI: 89.6–100%) and 99.0% (95% CI: 97.2–99.8%), respectively. In total, 5 samples were positive in the reference real-time RT-PCR assay and negative in the Smart Gene SARS-CoV-2 assay, whereas 5 samples were negative in the reference real-time RT-PCR assay and positive in the Smart Gene SARS-CoV-2 assay. CONCLUSION: Smart Gene SARS-CoV-2 showed sufficient analytical performance for the detection of SARS-CoV-2 in nasopharyngeal and anterior nasal samples.

Since its emergence in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide [1] . A quick and accurate diagnosis is essential for the clinical management of patients and infection control measures [2] . The expanding pandemic has increased the demand for laboratory tests and large-scale testing. Facility-based platforms using a high-capacity automated testing system are advantageous for meeting this demand. However, the time to perform the test and transport the samples to the laboratory are barriers to obtaining results in a timely manner.

A point-of-care (POC) test, which does not require extensive equipment or skilled technicians and which provides results in a short period, is beneficial for overcoming the disadvantages of large-scale laboratory testing. POC tests are helpful in situations like outbreaks in long-term care facilities, where an immediate diagnosis is needed [2] . Antigen tests are quicker and easier to use than nucleic acid amplification tests (NAAT) and are widely used as POC tests. However, a recent systematic meta-analysis of antigen test performance in real-world settings revealed that sensitivity ranges from 28.9% to 98.3% according to demographic features, viral load, and symptom state [3] . Thus, rapid and more reliable diagnostic tools are required.

Smart Gene SARS-CoV-2 (Mizuho Medy Co., Ltd., Tosu City, Saga, Japan) is a novel test kit for Smart Gene, an automated molecular testing platform that utilizes the quenching probe (QProbe) method. Because of its small size and fast turnaround time, Smart Gene can be installed in clinics and used for POC testing platforms, and has been used to diagnose pediatric respiratory infection of Mycoplasma pneumoniae [4] . In this prospective study, we evaluate the clinical performance of Smart Gene SARS-CoV-2 for nasopharyngeal and anterior nasal samples collected at a local PCR center.

In this study, we enrolled participants and collected samples at the PCR center in Tsukuba Medical Center Hospital (TMCH) between March 25 and July 5, 2021, which intensively collected nasopharyngeal samples for the PCR analysis of SARS-CoV-2 [5, 6, 7, 8, 9] . Subjects referred by 59 primary care facilities and a local public health center, as well as TMCH healthcare workers with suspected SARS-CoV-2 infection based on symptoms or a known contact history with COVID-19 confirmed/suspected patients were prospectively enrolled.

For the evaluation of nasopharyngeal samples, we obtained one additional nasopharyngeal sample for the evaluation of Smart Gene SARS-CoV-2, as previously described [6, 7] . For the evaluation of anterior nasal samples, we obtained two additional anterior nasal samples, as previously described [5] , for the Smart Gene SARS-CoV-2 and reference real-time RT-PCR assays. The Sponge swab™ (NIPRO, Osaka, Japan), equipped with a Smart Gene SARS-CoV-2 kit, was used for obtaining samples for the Smart Gene SARS-CoV-2 assay and the FLOQ swab™ (Copan Italia S.p.A., Brescia, Italy) was used for obtaining samples for in-house reverse transcription (RT)-PCR and reference real-time RT-PCR assays.

All subjects provided their consent for enrollment. If multiple samples were collected from the same subject, they were all treated as individual samples. The ethics committee of TMCH approved the present study (approval number: 2021-008).

The evaluation of Smart Gene SARS-CoV-2 was performed using fresh samples according to the manufacturer's instructions, as described in the package insert. An overview of the test procedure is shown in Figure 1 . Briefly, the collected sample with the sponge swab J o u r n a l P r e -p r o o f was suspended with 1 mL of extraction reagent solution in a vial, and the suspended sample was dripped into the cartridge. The cartridge was inserted into the analyzer and the fully automated PCR analysis was performed after a few touch-steps. A PCR result was considered "positive" when the Ct value was ≤45.

The swabs were suspended in 3 mL of Universal Transport Medium™ (UTM™) (Copan diagnostics, Brescia, Italy). Purification and RNA extraction from UTM™ samples were performed with magLEAD ® 6gC (Precision System Science, Chiba, Japan). The purified samples were evaluated by GENECUBE ® and GENECUBE ® HQ SARS-CoV-2 as an in-house RT-PCR assay [8] .

After used for the in-house PCR, the purified samples were frozen at -80 °C and transferred to Mizuho Medy for the reference real-time RT-PCR assay. The N1 and N2 primer/probe set (Nihon Gene Research Laboratories, Miyagi, Japan) were employed for the reference real-time RT-PCR assay, as suggested by the "Manual for the Detection of J o u r n a l P r e -p r o o f Pathogen 2019-nCoV Ver. 2.9.1" issued by the National Institute of Infectious Diseases of Japan (NIID) [10] . The reference real-time RT-PCR assays were performed on a LightCycler ® Nano System (Roche Diagnostics, Rotkreuz, Switzerland) using One Step PrimeScript™ III RT-qPCR Mix (Takara Bio, Kusatsu, Japan) with the following cycling conditions: reverse transcription at 52°C for 5 min and 95°C for 10 s, and 45 cycles at 95°C for 5 s and at 60°C for the 30s. A PCR result was considered "positive" when the Ct value was ≤40 [10] . The absolute viral copy number was determined by serially diluted RNA control targeting the N2 gene of SARS-CoV-2 (Nihon Gene Research Laboratories). For the comparison between the Ct values of Smart Gene SARS-CoV-2 and the reference real-time RT-PCR assay, we used the Ct values of N2 gene. Figure 1) , and negative samples were also prepared. The viral concentration for UTM was 1,824 copies/mL, 912 copies/ mL, 456 copies/mL, 228 copies/ mL, and 0 copy/mL respectively.

For evaluation of the LOD, a total of 24 replicate analyses (8 for pooled sample 1, 8 for pooled sample 2, 8 for UTM) for the reference real-time RT-PCR assay, and 12 replicate analyses (4 for pooled sample 1, 4 for pooled sample 2, 4 for extraction reagent solution) for Smart Gene SARS-CoV-2 were performed for each viral concentration. The N2 primer/probe set of the NIID method was used for the reference real-time RT-PCR assay. The lowest viral load at which a 100% detection rate was achieved was considered to be the LOD of the assay.

The 95% confidence intervals (CIs) of total, positive and negative concordance rate 

The results of the LOD tests using recombinant SARS-CoV-2 are shown in Table 2 and the detailed data are summarized in Supplementary Table 1 (Table 1c) . For the overall evaluation of nasopharyngeal and anterior nasal samples (Table 1a) Currently, several POC-type molecular assays have been available worldwide [3] , and their sensitivities and specificities were generally as high as above 90% [3, 12, 13] . Our study indicated that Smart Gene SARS-CoV-2 has comparable diagnostic performance to other POC molecular tests [3, 12, 13] despite having modest turnaround time (Table 3 ). In the evaluations of LOD and clinical performance, Smart Gene SARS-CoV-2 provided almost identical results to the reference real-time RT-PCR. Table 3 Table 3a and 3b and Supplementary Figure 3 ).

Our study was associated with some limitations. First, we did not analyze the sequences of the viruses detected in this study. Thus, the effect of genetic mutation on the performance of Smart Gene SARS-CoV-2 was not evaluated. Second, this study was conducted in a limited season and area, and it may be necessary to verify whether similar results can be obtained throughout the year or in another area. Finally, the reference real-time RT-PCR assay used frozen stored purified extraction, and such storage and transportation methods may have affected the test results.

In conclusion, current study showed that Smart Gene SARS-CoV-2 had sufficient analytical performance in the detection of SARS-CoV-2 in nasopharyngeal and anterior nasal samples. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update

Guidance for SARS-CoV-2 Point-of-Care and Rapid Testing 2021

point-ofcare antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection

Clinical Evaluation of a Novel Point-of-Care Assay To Detect Mycoplasma pneumoniae and Associated Macrolide-Resistant Mutations

Diagnostic performance and characteristics of anterior nasal collection for the SARS-CoV-2 antigen test: a prospective study

The evaluation of a newly developed antigen test (QuickNavi™-COVID19 Ag) for SARS-CoV-2: A prospective observational study in Japan

The evaluation of a novel digital immunochromatographic assay with silver amplification to detect SARS

A Prospective Evaluation of the Analytical Performance of GENECUBE ® HQ SARS-CoV-2 and GENECUBE ® FLU A/B

Prospective analytical performance evaluation of the QuickNavi™-COVID19 Ag for asymptomatic individuals

Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan

Molecular diagnostic technologies for COVID-19: Limitations and challenges

Clinical performance of the point-of-care cobas liat for detection of SARS-CoV-2 in 20 minutes: A J o u r n a l P r e -p r o o f multicenter study

Detection of SARS-CoV-2 by Use of the Cepheid Xpert Xpress SARS-CoV-2

CoV-2 Assays

Viral Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in COVID-19. Diagnostics (Basel)